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Purpose: To assess the effect of preservative-free dorzolamide–timolol on nonvisual   symptoms 
and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle 
glaucoma or ocular hypertension.
Methods: This was a prospective, 8-week, open-label, Canadian multicenter study. All patients 
were treated with preservative-free dorzolamide–timolol formulation. The primary outcome was 
the change in the nonvisual symptom score of the Glaucoma Symptom Scale (GSS-SYMP-6) 
from baseline to 8 weeks. Secondary effectiveness outcome measures were absolute and percent 
changes in IOP from baseline to 4 and 8 weeks.
Results: One hundred and seventy-eight patients were enrolled. Mean (SD) age was 65.6 
(12.1) years and 90 (50.6%) were females. There were 92 patients diagnosed with open-angle 
glaucoma, 62 with ocular hypertension, and 23 with both diseases (diagnosis was missing for 
one patient). The mean (SD) GSS-SYMP-6 score increased from 73.6 (21.8) at baseline to 76.1 
(20.7) at 8 weeks (P = 0.097). Mean (SD) IOP significantly decreased by 11.7 (5.1) mmHg at 
4 weeks (P , 0.001) and by 11.5 (5.3) mmHg at 8 weeks (P , 0.001), representing reductions 
of -38.5% (P , 0.001) and  -38.0% (P , 0.001), respectively.
Conclusion: Preservative-free dorzolamide–timolol does not increase eye discomfort while 
significantly reducing IOP in patients with open-angle glaucoma or ocular-hypertension.
Keywords: open-angle glaucoma, ocular hypertension, GSS-SYMP-6, intraocular pressure, 
dorzolamide–timolol, preservative-free
Introduction
Open-angle glaucoma is a chronic progressive disease characterized by asymptomatic 
elevation of intraocular pressure (IOP), progressive optic nerve damage, and visual 
field loss that can lead to blindness.1 Glaucoma is the second leading cause of blindness 
worldwide2 and in Canada,3 and its incidence increases with advancing age.4,5
Currently, the goal of glaucoma therapy is to reduce the rate of retinal ganglion 
cell loss by decreasing IOP.6 Since open angle-glaucoma and ocular hypertension are 
progressive chronic conditions, their management requires long-term and even life-
long treatment. As with all chronic conditions, treatment benefits must be balanced 
against possible risk for side effects. In addition, tolerability of long-term treatment 
becomes an important factor contributing to therapeutic effectiveness given its impact 
on compliance. Therefore, the aim of glaucoma therapy is the reduction of IOP and 
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preservation of visual field and vision while reducing the 
impact of chronic therapy and potential side effects on the 
patients’ quality of life.
Dorzolamide, a topical carbonic anhydrase inhibitor, 
and timolol, a nonselective beta receptor blocking agent, are 
both effective in the management of elevated IOP, and are 
well established as ocular hypotensive treatments. Further, 
they have an additive IOP-lowering effect when administered 
concomitantly.7 Several clinical trials have demonstrated 
the efficacy of dorzolamide–timolol fixed   combination 
in the treatment of open-angle glaucoma and ocular 
hypertension.8–19 However, the preservative agents included in 
the formulation of these eye-drop therapies have been shown 
to decrease the stability of the precorneal tear film and to have 
a detergent effect on the lipid layer;   resulting in increased 
evaporation, dry-eyes,20 and   irritation.21   Preservative-free eye 
drops may therefore be useful in the efforts to protect and 
maintain ocular surface integrity, especially as over 50% of 
patients treated for glaucoma have concurrent ocular surface 
disorders.20,22,23 Indeed, preservative-free medications could 
provide an effective alternative for long-term treatment 
of glaucoma and ocular hypertension for patients who are 
sensitive to a preservative and those with a history of dry 
or irritated eyes.
The principal aim of this study was to describe the change 
in nonvisual ocular symptoms in newly diagnosed patients 
with open-angle glaucoma or ocular hypertension treated 
with a preservative-free dorzolamide-timolol formulation.
Materials and methods
Study design
This was an 8-week prospective, multicenter, open-label 
study performed in 18 Canadian ophthalmologists’   clinics 
between May 2007 and October 2008. Assessments were per-
formed at baseline (week 0), and at 4 and 8 weeks of   treatment 
at the treating ophthalmologists’ clinics. At each study visit, 
patients completed the six-item nonvisual   symptom scale 
(GSS-SYMP-6) extracted from the 10-item glaucoma symp-
tom scale (GSS).24 The six nonvisual   symptoms assessed 
were: i. burning, smarting and stinging, ii. tearing, iii. dry-
ness, iv. itching, v. soreness and   tiredness, and vi. feeling of 
something in the eye. Patients were asked to rate each of these 
six nonvisual symptoms using a   five-point Likert Scale with 0 
being very bothersome and 4   representing the absence of the 
symptom. The score of this scale was transformed between 
0 and 100 with lower scores indicating higher severity of 
the nonvisual symptoms. A score of 100 was the best pos-
sible score and positive changes indicate improvement in 
the patient’s condition. In addition, at each study visit, the 
treating ophthalmologists measured the IOP in patients’ both 
eyes using a calibrated Goldmann’s applanation tonometer. 
This was calculated as the mean of two consecutive and inde-
pendent measures in the same eye. Patients were assessed at 
any time during the day. However, each patient was assessed 
at approximately the same time of the day at all visits.
The study was approved by an Independent Ethics Review 
Board (Insitutional Review Board Services, Aurora, Ontario) 
and was conducted in accordance with the International 
Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) “Good 
Clinical Practice guidelines”, the World Medical Association 
Declaration of Helsinki and all applicable local regulations. 
A written informed consent was obtained from every patient 
prior to conducting any study related procedures including 
the evaluation of study eligibility and enrolment.
Patients
Eligible patients ($18 years) were recently diagnosed with 
open-angle glaucoma or ocular hypertension according to 
the Canadian Ophthalmological Society evidence-based 
clinical practice guidelines.25 Open-angle glaucoma was 
diagnosed when there was evidence of glaucomatous optic 
neuropathy (GON), with or without elevated IOP, while 
ocular   hypertension was diagnosed when IOP was elevated, 
but without evidence of GON or visual field damage. Eligible 
patients also had an IOP of $27 mmHg in at least one eye 
and a baseline GSS-SYMP-6 total score of 75 or less. All 
were treatment-naive. In addition, patients may have been 
either sensitive to a preservative or had “less than perfect” 
ocular surface issues, as per the clinical judgment of the 
treating ophthalmologist.
Patients were excluded from the study if they had 
any   fundus pathology likely to change during the study 
or to   influence IOP, hypersensitivity to any component 
of preservative-free dorzolamide–timolol, severe renal 
impairment (serum creatinine .150 µmol/L or creatinine 
clearance ,30 mL/min), or any contraindication to the 
use of preservative-free dorzolamide–timolol including 
  bronchospasm (eg, bronchial asthma or any history of 
  bronchial asthma and chronic obstructive pulmonary disease) 
or sinus bradycardia, or second or third degree AV block, or 
overt cardiac failure or cardiogenic shock). Patients with a 
history of diabetic retinopathy were eligible for inclusion in 
the study. Prohibited concomitant medications were   carbonic 
anhydrase inhibitors (systemic and topical),   systemic 
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(eg,   clonidine, corticosteroids or oral   beta-blocking agents), 
and any medications   containing one of the following pre-
servative agents: benzalkonium chloride, benzododecinium 
bromide, or stabilized oxychloro complex.
Treatment
All patients were treated with the preservative-free formula-
tion of dorzolamide–timolol (COSOPT® without benzalko-
nium chloride as preservative, Merck Frosst Canada Ltd, 
Kirkland, Canada) for eight weeks on a self-administered 
regimen of one drop, twice daily in the morning and bedtime, 
in each affected eye.
Outcome measures
The primary outcome measure was the change in GSS-
SYMP-6 score from baseline to 8 weeks of treatment. 
  Secondary outcome measures were the mean absolute 
change in GSS-SYMP-6 score from baseline to 4 weeks 
of   treatment. The presence and severity of the nonvisual 
symptoms in patients’ worse eye, defined as the eye with 
the highest IOP measure at baseline, were also described 
at each visit. Therapeutic effectiveness outcomes were the 
absolute and percent changes in IOP measured in the worse 
eye from baseline to 4 and 8 weeks of treatment. Patient and 
  ophthalmologist satisfaction with treatment after 8 weeks 
were assessed with a five-point Likert scale question ranging 
from 0 (very   dissatisfied) to 4 (very satisfied). Compliance 
with study treatment was also assessed by self-reporting at 
4 and 8 weeks during clinic visits. Patients who reported 
  missing more than 20% of scheduled doses were   considered 
non-compliant. Safety was assessed by the incidence of 
adverse events that occurred during treatment and up to 
14 days after study drug discontinuation.
Statistical methods
A difference of seven points was observed in the SYMP-6 
validation study,24 in which patients with glaucoma had a 
mean (SD) score of 78 (23) compared to 85 (21) for the 
reference group. The present study sought to detect this 
clinically significant difference of seven points. With an 
80% power and allowing for 10% drop out rate, a minimum 
of 170 patients were to be enrolled.
Descriptive statistics including the mean and standard 
deviation for continuous variables and frequency distributions 
for discrete variables were reported. The statistical signifi-
cance of the change in GSS-SYMP-6 score from baseline to 4 
and 8 weeks was assessed with the Student’s t-test for paired 
observations. The 95% confidence   intervals of the mean 
change were also computed as measures of precision and to 
allow inference to the target   population. χ2 statistics were used 
to test the difference in the presence of nonvisual symptoms 
and to assess the change in the distribution of the symptom 
severity from baseline to 4 and 8 weeks of treatment.
The statistical significance of the mean absolute and 
percent change in IOP was assessed with the Student’s t-test 
for paired observations. For this outcome, 95% confidence 
intervals were also computed. The observed mean absolute 
change in IOP from baseline to 4 and 8 weeks was   compared 
to the conventional value of zero (Ho: δ = 0 mmHg) and 
to the a priori established value of -4.0 mmHg (Ho: 
δ # -4.0 mmHg). The test value for the comparison of the 
observed mean percent change in IOP was of -20% (Ho: 
δ # -20.0%). An absolute change of -4.0 mmHg or percent 
change of -20.0% were considered as the minimum for 
  clinical significance.
All analyses were based on observed cases and no 
  imputation methods were used for replacing missing data. 
As per the intention-to-treat (ITT) principle, all patients 
with outcome measurements at baseline and one of the 
follow-up visits were included in the analyses regardless 
of protocol violations and compliance with treatment. The 
minimum level of statistical significance was a priori defined 
at 5%. All statistical analyses were performed using STATA 
(  version 10.0; College Station, TX) and SPSS   (version 12.0 
for Windows; SPSS Inc, Chicago, IL).
Results
Patient disposition
A total of 178 patients formed the ITT population and were 
included in the study. Of these, 169 (94.9%) and 176 (98.9%) 
were assessed at 4 and 8 weeks, respectively. There were 
9 (5.1%) patients who were discontinued from the study: 
2 (1.1%) patients withdrew consent, 3 (1.7%) were lost to 
follow-up, 1 (0.6%) experienced a serious adverse event, 
and 3 (1.7%) were discontinued for other reasons. Seven of 
the discontinued patients were retrieved drop-outs that were 
included in the 8-week assessment based on their visit date.
Patient demographics
The patient demographics are summarized in Table 1. The 
mean (SD) age of the 178 patients included in the study was 
65.6 (12.1) years; 21 (11.8%) were #52 years of age and 
58 (32.6%) were .72 years. The majority were Caucasian 
(n = 168; 94.4%) and 90 (50.6%) were females. A total of 
92 patients were diagnosed (worse eye) with open-angle 
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diseases; diagnosis was missing for 1 patient. There were 
125 patients (70.2%) who had both eyes affected by either 
open-angle glaucoma or ocular hypertension.
Effectiveness
The GSS-SYMP-6 scores for the worse eye were   available 
for 122 patients at baseline, 115 at 4 weeks, and 113 at 
8 weeks. The mean (SD) GSS-SYMP-6 score increased from 
73.6 (21.8) at baseline to 74.5 (19.3) at 4 weeks and 76.1 
(20.7) at 8 weeks of treatment (Table 2). The mean (SD) 
absolute changes in GSS-SYMP-6 scores from baseline to 
4 and 8 weeks of treatment were 1.8 (16.9) and 3.2 (20.2), 
respectively (Table 2).
Table 3 describes the presence and severity of nonvisual 
symptoms in the worse eye at baseline, 4, and 8 weeks of 
treatment. While the presence of burning, smarting, and 
stinging symptoms significantly increased from 28.0% at 
baseline to 63.0% at 4 weeks (P , 0.001), and 61.9% at 
8 weeks (P , 0.001), there was no statistical difference 
in the presence of these symptoms between 4 and 8 weeks 
of treatment (P = 0.859). The proportion of patients with 
itching was reduced from 49.2% at baseline to 35.7% at 
4 weeks (P = 0.028) and 35.2% at 8 weeks (P = 0.023). From 
baseline to 8 weeks of treatment, decreases in the presence 
of the following symptoms were observed: dryness (39.4% 
to 28.8%; P = 0.074), and soreness and tiredness (49.2% to 
36.0%; P = 0.032). The severity profile of these symptoms 
did not change during the course of the study.
The IOP measurements at each study visit and the mean 
absolute changes in IOP from baseline to 4 and 8 weeks 
of treatment are presented in Table 4. The mean (SD) IOP 
decreased from 29.6 (4.2) mmHg at baseline to 18.1 (3.7) 
mmHg at 4 weeks and 18.1 (3.9) mmHg at 8 weeks of 
treatment. The mean (SD) absolute reduction in IOP from 
baseline to 4 weeks was -11.7 (5.1) mmHg (P , 0.001) and 
-11.5 (5.3) mmHg (P , 0.001) at 8 weeks. These changes 
were significantly higher than the test value of -4.0 mmHg 
(P , 0.001). At 4 and 8 weeks, a total of 156 (92.3%) and 158 
(89.8%) patients achieved a clinically significant   reduction 
in IOP of at least 4.0 mmHg, respectively.
Figures 1 and 2 depict the distribution of the mean 
  percent change in IOP from baseline to 4 and 8 weeks of 
treatment. The mean (SD) percent reduction in IOP was 
38.5% (13.0) at 4 weeks (P , 0.001) and 38.0% (14.73) at 
Table 2 Glaucoma nonvisual symptoms scale (GSS-SYMP-6) measurements
Visits N Mean (SD) 95% CI P-values 
Lower limit Upper limit
Baseline (week 0) 122a 73.6 (21.8) 69.5 77.1 –
Week 4 115b 74.5 (19.3) 71.1 78.1 –
  Absolute change from baseline 114c 1.8 (16.9) -1.3 4.9 0.260
Week 8 113d 76.1 (20.7) 72.3 79.7 –
  Absolute change from baseline 111e 3.2 (20.2) -0.6 7.0 0.097
Notes: aThe GSS-SYMP-6 was not completed for both eyes at baseline by 56 of the 178 patients. bThe GSS-SYMP-6 was not completed for both eyes at week 4 by 54 of the 
169 patients. cThe GSS-SYMP-6 was not completed for both eyes at baseline and week 4 by 55 of the 169 patients. dThe GSS-SYMP-6 was not completed for both eyes at 
week 8 by 63 of the 176 patients. eThe GSS-SYMP-6 was not completed for both eyes at baseline and week 8 by 65 of the 176 patients. 
Abbreviation: CI, confidence interval.
Table 1 Demographics of the 178 patients included in the study
Characteristics n %
Age (years)a
 # 52 21 11.8
 . 52 to #72 97 54.5
 . 72 58 32.6
Gender
  Male 88 49.4
  Female 90 50.6
Race
  Caucasian 168 94.4
  Black 3 1.7
  Hispanic 2 1.1
  Asian 4 2.3
  Other 1 0.6
Worse eyeb
  Left eye 97 54.5
  Right eye 81 45.5
Presence of open-angle glaucoma
  Left eye 91 51.1
  Right eye 102 57.3
Presence of ocular hypertension
  Left eye 76 42.7
  Right eye 82 46.1
Presence of glaucoma or ocular 
hypertension in both eyes
125 70.2
Medical history
    Family history of open-angle glaucoma 
or ocular hypertension
42 23.6
  Type I diabetes 4 2.3
  Type II diabetes 37 20.8
  Hypertension 53 29.8
  Myopia 35 19.7
  Migraine/headache 18 10.1
Notes: aThe age of 2 (1.1%) patients was unknown. bThe worse eye was defined as 
the eye with the highest intraocular pressure measure at baseline.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 3 Presence and severity of the nonvisual symptoms in the worse eye
Nonvisual symptoms 
(GSS-SYMP-6)*
Baseline 
(N = 132)a
Week 4 
(N = 127)b,c
Week 4 
vs Baseline 
P-value
Week 8 
(N = 125)d,e
Week 8 
vs Baseline 
P-value n % n % n %
Burning, smarting, stinging
  Absence of symptom 95 72.0 47 37.0 ,0.001 48 38.1 ,0.001
  Presence of symptom 37 28.0 80 63.0 78 61.9
    Very bothersome 5 13.5 6 7.5 0.356 6 7.7 0.219
    Somewhat bothersome 11 29.7 21 26.3 18 23.1
    A little bothersome 19 51.4 50 62.5 50 64.1
    Not at all bothersome 2 5.4 3 3.8 4 5.1
Tearing
  Absence of the symptom 75 56.8 61 48.0 0.158 64 51.2 0.367
  Presence of the symptom 57 43.2 66 52.0 61 48.8
    Very bothersome 7 12.3 4 6.1 0.129 7 11.5 0.233
    Somewhat bothersome 18 31.6 18 27.3 14 23.0
    A little bothersome 29 50.9 37 56.1 33 54.1
    Not at all bothersome 3 5.3 7 10.6 7 11.5
Dryness
  Absence of the symptom 80 60.6 87 68.5 0.185 89 71.2 0.074
  Presence of the symptom 52 39.4 40 31.5 36 28.8
    Very bothersome 13 25.0 6 15.0 0.106 4 11.1 0.057
    Somewhat bothersome 19 36.5 11 27.5 9 25.0
    A little bothersome 15 28.8 19 47.5 22 61.1
    Not at all bothersome 5 9.6 4 10.0 1 2.8
Itching
  Absence of the symptom 67 50.8 81 64.3 0.028 81 64.8 0.023
  Presence of the symptom 65 49.2 45 35.7 44 35.2
    Very bothersome 5 7.7 1 2.2 0.220 3 6.8 0.274
    Somewhat bothersome 15 23.1 8 17.8 5 11.4
    A little bothersome 40 61.5 32 71.1 33 75.0
    Not at all bothersome 5 7.7 4 8.9 3 6.8
Soreness, tiredness
  Absence of the symptom 67 50.8 81 63.8 0.035 80 64.0 0.032
  Presence of the symptom 65 49.2 46 36.2 45 36.0
    Very bothersome 6 9.2 1 2.2 0.217 2 4.4 0.091
    Somewhat bothersome 24 36.9 16 34.8 11 24.4
    A little bothersome 30 46.2 24 52.2 28 62.2
    Not at all bothersome 5 7.7 5 10.9 4 8.9
Feeling of something in the eye
  Absence of the symptom 84 63.6 89 70.1 0.272 83 66.4 0.643
  Presence of the symptom 48 36.4 38 29.9 42 33.6
    Very bothersome 6 12.5 4 10.5 0.472 6 14.3 0.544
    Somewhat bothersome 11 22.9 8 21.1 7 16.7
    A little bothersome 29 60.4 22 57.9 25 59.5
    Not at all bothersome 2 4.2 4 10.5 4 9.5
Notes: *Glaucoma symptom scale. aAt baseline, the GSS-SYMP-6 was not completed for the worse eye by 46 of the 178 patients. bAt week 4, the GSS-SYMP-6 was not 
completed for the worse eye by 42 of the 169 patients. cN = 126 for itching nonvisual symptom; at week 4, the itching nonvisual symptom was not completed for the worse 
eye by 43 of the 169 patients. dAt week 8, the GSS-SYMP-6 was not completed for the worse eye by 51 of the 176 patients. eN = 126 for burning, smarting and stinging 
symptoms; at week 8, burning, smarting and stinging symptoms were not completed for the worse eye by 50 of the 176 patients.
8 weeks (P , 0.001). A clinically significant IOP reduction 
of at least 20% at 4 and 8 weeks of treatment was observed 
for 153 (90.5%) and 154 (87.5%) patients, respectively.
Figure 3 summarizes the results of the patient and 
ophthalmologist global satisfaction with treatment rating 
after 8 weeks of therapy. After 8 weeks of treatment, 144 
(81.8%) patients were either satisfied or very satisfied with 
the   preservative-free dorzolamide-timolol formulation, 
while 9 (5.1%) patients were either dissatisfied or very 
dissatisfied with treatment. After 8 weeks of treatment, 
the   ophthalmologists were either satisfied or very satisfied 
with the preservative-free dorzolamide-timolol formula-
tion for 155 (88.1%) of the patients, while they were either 
  dissatisfied or very dissatisfied for 7 (3.9%) of them.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 4 Intraocular pressure (IOP) measurements (mmHg) in the worse eye
Visits N Mean (SD) 95% CI P-values 
Lower limit Upper limit H0: δ = 0 H0: δ = -4
Baseline (Week 0) 178 29.6 (4.2) 29.0 30.2 – –
Week 4 165a 18.1 (3.7) 17.5 18.7 – –
  Absolute change from baseline 165b -11.7 (5.1) -12.5 -10.9 ,0.001 ,0.001
Week 8 167c 18.1 (3.9) 17.5 18.8 – –
  Absolute change from baseline 166d -11.5 (5.3) -12.3 -10.7 ,0.001 ,0.001
Notes: aIOP measurement at week 4 was not available for 4 of the 169 patients. bIOP measurements at baseline and week 4 were not available for 4 of the 169 patients. 
cIOP measurement at week 8 was not available for 9 of the 176 patients. dIOP measurements at baseline and week 8 were not available for 10 of the 176 patients. 
Abbreviations: SD, standard deviation; CI, confidence interval; δ, difference.
Adherence to treatment was high. There were 162 (95.8%) 
and 159 (90.3%) patients who were $80% compliant with 
treatment at 4 and 8 weeks, respectively. At 4 weeks, 107 
(63.3%) patients reported perfect adherence (taking 100% of 
their medication) while another 55 (32.5%) reported adherence 
(taking 80%–99.9% of their study medication). Similar results 
were obtained at week 8, with 106 (60.2%) patients reporting 
perfect adherence and another 53 (30.1%) reporting adher-
ence. The median missed dose at each visit was 0.0 drops.
Safety
During the course of this 8-week study, three serious adverse 
events were experienced by three patients. A 67-year-old 
female experienced a retinal vein occlusion that was 
  considered by the treating ophthalmologist to be probably not 
related to study medication. A 95-year-old male had   nausea 
and another 61-year-old male experienced bradycardia. 
These two events were considered to be definitely related 
to the study medication; however, both patients recovered 
without any sequelae or permanent disability. The patient 
who had nausea discontinued study medication after 2 weeks 
of treatment.
Discussion
This was the first Canadian observational study aimed at 
assessing nonvisual ocular symptoms and the   effectiveness 
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of preservative-free dorzolamide–timolol   formulation in 
a   real-life setting. The results of this study showed that 
  treatment with preservative-free dorzolamide–timolol 
does not increase discomfort related to nonvisual ocular 
symptoms, while maintaining therapeutic effectiveness in 
reducing IOP.
It is postulated that discomfort with eye-drop therapy 
can lead to patient discontinuation of treatment.26–28 
While a small increase in GSS-SYMP-6 score (indicating 
  improvement) was observed in the current study, this increase 
was   neither statistically nor clinically significant. The use of 
the preservative-free formulation therefore did not increase 
eye discomfort, which may have been an important factor 
  contributing to high compliance with therapy. This could 
result in optimization of long-term treatment effectiveness.
In this study, over 80% of patients and ophthalmologists 
were satisfied with the preservative-free dorzolamide–timolol 
formulation. From the perspective of the patient, the high 
level of satisfaction can be mainly explained by the   reduction 
in dryness, itching, soreness, and tiredness in the eyes. This 
could contribute to improved quality of life during the course 
of treatment. From the perspective of the physician, the 
high level of satisfaction reported by the   ophthalmologists 
may be due to the observed therapeutic effectiveness of 
the preservative-free dorzolamide–timolol formulation in 
  reducing IOP. The magnitude of IOP reduction observed in 
these patients is likely associated with their treatment-naïve 
drug status since more robust IOP reduction is known to 
occur in treatment-naïve patients.
In the current study, self-administration of   preservative-free 
dorzolamide–timolol during eight weeks produced an IOP 
reduction of approximately 40%, which exceeds the treatment 
targets established by the American Academy of Ophthal-
mology and the European Glaucoma Society. In fact, the 
American Academy of Ophthalmology currently recom-
mends IOP lowering of at least 20% from baseline IOP29 and 
the European Glaucoma Society recommends lowering of at 
least 30% from baseline IOP.30
The observed change in IOP is comparable but higher 
than that generally reported by randomized clinical trials 
of dorzolamide–timolol,7,8,15,18,31–34 further supporting the 
efficacy of dorzolamide–timolol. Importantly, the present 
study indicates that the absence of preservative did not seem 
to thwart the efficacy. It is conceivable that by disrupting 
the corneal epithelium, preservatives partially contribute 
to ocular penetration and hence, therapeutic effectiveness. 
The results in this study suggest that preservative-induced 
effects on the ocular surface are not necessary for the drug 
efficacy. Since there is no difference in efficacy between 
preserved and preservative-free formulations,26,35,36 the cur-
rent study further suggests that the dorzolamide–timolol 
  preservative-free   formulation may constitute an advantageous 
treatment   alternative that provides a better tolerability for 
patients sensitive to preservative or for whom the utilization 
of preservative-free formulation is otherwise advisable.
Limitations of the current study relate to the open-label, 
single cohort design that did not include a comparative 
group. The study design was thus not amenable to answer 
some potentially interesting questions. For instance, recent 
observations from daily practice indicate that while most 
patients are satisfied with their medication, 9% of new 
users had their medication stopped by their   ophthalmologist 
due to side effect.28 Comparing the nonvisual symptoms 
between various treatments or between preserved and 
unpreserved formulations of dorzolamide–timolol would 
have been informative. However, the principal objective of 
the   present study was to measure changes in eye comfort 
from baseline to 8 weeks of treatment with preservative-free 
  dorzolamide–timolol formulation and not to perform between 
treatment group comparisons. By conducting within- instead 
of between-group comparison, all possible confounding 
bias related to disease and lifestyle factors that may affect 
IOP changes were avoided since each patient provided both 
control (pretreatment) and on treatment data.37 Further, a 
blinded treatment regimen would not have been compatible 
with a clinical practice setting. The current single-cohort, 
open-label, prospective design was thus implemented in order 
to achieve study objectives and to more accurately reflect 
real-life clinical settings.
An important strength of this study is the generaliz-
ability of its results to the Canadian target population. This 
study was conducted in real-life clinical settings where 
physicians treated patients as per their clinical judgment 
within the   constraints of their clinical practice. These 
  characteristics thus better emulate the routine clinical   practice 
and permit the assessment of real-life effectiveness and 
safety. In   addition, the use of a standardized and validated 
questionnaire (the GSS)24 to assess the ocular symptoms 
  experienced by the patients enhances study validity.24 Based 
on their baseline scores, patients enrolled in this study likely 
  represent the patient population who would benefit from the 
  preservative-free medication.
In conclusion, the results of this study conducted in 
a   real-life setting demonstrated that preservative-free 
  dorzolamide–timolol formulation does not increase eye dis-
comfort while significantly reducing intra–ocular pressure in Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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treatment-naïve, newly diagnosed patients with open-angle 
glaucoma or ocular hypertension. Future real-life studies 
assessing the relative difference in nonvisual symptoms 
between various glaucoma treatments and between   preserved 
and unpreserved formulations of   dorzolamide–timolol, would 
further contribute to the management of glaucoma.
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